ProCE Banner Activity

What’s New in the Treatment of Relapsed SCLC

Clinical Thought

Here I share my thoughts on recent clinical data for 2 novel agents showing promise in the treatment of relapsed SCLC: tarlatamab, a DLL3-targeted T-cell engager, and ifinatamab deruxtecan, a B7-H3–directed antibody–drug conjugate.

Released: January 22, 2024

Share

Faculty

Mark A. Socinski

Mark A. Socinski, MD

Executive Medical Director
AdventHealth Cancer Institute
Orlando, Florida

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Amgen and AstraZeneca Pharmaceuticals.

Amgen

AstraZeneca Pharmaceuticals

Faculty Disclosure

Primary Author

Mark A. Socinski, MD

Executive Medical Director
AdventHealth Cancer Institute
Orlando, Florida

Mark A. Socinski, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol-Myers Squibb, G1 Therapeutics, Genentech, Gilead, Guardant, Janssen, Jazz, Lilly, Merck, Mirati, OncoC4, Regeneron, Spectrum, Summit.